Spotting a gem from transpacific biotech, AstraZeneca pays $25M cash to pick up a preclinical bispecific antibody

Looking to expand its oncology pipeline, AstraZeneca has turned to the east to pick up a next-gen drug against an emerging target.

Harbour BioMed, a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Spot­ting a gem from transpa­cif­ic biotech, As­traZeneca pays $25M cash to pick up a pre­clin­i­cal bis­pe­cif­ic an­ti­body